Lineage Tracing Evidence for In Vitro Dedifferentiation but Rare Proliferation of Mouse Pancreatic β-Cells
- 1Department of Cellular Biochemistry and Human Genetics, The Hebrew University-Hadassah Medical School, Jerusalem, Israel
- 2Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- Address correspondence and reprint requests to Yuval Dor, Department of Cellular BiochemistryHuman Genetics, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. E-mail dor{at}md.huji.ac.il
Abstract
Understanding and manipulating pancreatic β-cell proliferation is a major challenge for pancreas biology and diabetes therapy. Recent studies have raised the possibility that human β-cells can undergo dedifferentiation and give rise to highly proliferative mesenchymal cells, which retain the potential to redifferentiate into β-cells. To directly test whether cultured β-cells dedifferentiate, we applied genetic lineage tracing in mice. Differentiated β-cells were heritably labeled using the Cre-lox system, and their fate in culture was followed. We provide evidence that mouse β-cells can undergo dedifferentiation in vitro into an insulin-, pdx1-, and glut2-negative state. However, dedifferentiated β-cells only rarely proliferate under standard culture conditions and are eventually eliminated from cultures. Thus, the predominant mesenchymal cells seen in cultures of mouse islets are not of a β-cell origin.
- BrdU, bromodeoxyuridine
- HPAP, human placental alkaline phosphatase
- JDRF, Juvenile Diabetes Research Foundation
- PC1/3, prohormone convertase 1/3
- YFP, yellow fluorescent protein
Footnotes
-
Published ahead of print at http://diabetes.diabetesjournals.org on 15 February 2007. DOI: 10.2337/db06-1654.
-
Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db06-1654.
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted February 5, 2006.
- Received November 27, 2006.
- DIABETES














